中国临床药理学杂志

姜黄素与西达苯胺基于IFN-RIG-I-MAVS通路协同抑制乳腺癌细胞恶性行为的研究

PDF下载

潘越 ¹ , 张臣鸣 ²

中国临床药理学杂志 | 临床与基础桥接研究 2026,42(1): 59-65

收起

中国临床药理学杂志 |临床与基础桥接研究 2026 , 42 (1) : 59 -65

姜黄素与西达苯胺基于IFN-RIG-I-MAVS通路协同抑制乳腺癌细胞恶性行为的研究

全屏

[Author(id=1292126439143399815, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1292126436094140797, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1292126439256646025, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1292126436094140797, authorId=1292126439143399815, language=EN, stringName=Yue PAN, firstName=Yue, middleName=null, lastName=PAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=^1.Department of Thoracic Surgery, Wuhan Third Hospital, Wuhan 430061, Hubei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1292126439323754890, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1292126436094140797, authorId=1292126439143399815, language=CN, stringName=潘越, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=^1.武汉市第三医院胸外科，湖北武汉 430061, bio={"content":"

潘越（1992-），女，主治医师，主要从事乳腺癌及肺癌方面的临床工作和研究

"}, bioImg=null, bioContent=

潘越（1992-），女，主治医师，主要从事乳腺癌及肺癌方面的临床工作和研究

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1292126438807855488, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1292126436094140797, xref=1., ext=[AuthorCompanyExt(id=1292126438816244097, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1292126436094140797, companyId=1292126438807855488, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=^1.Department of Thoracic Surgery, Wuhan Third Hospital, Wuhan 430061, Hubei Province, China), AuthorCompanyExt(id=1292126438828827010, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1292126436094140797, companyId=1292126438807855488, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=^1.武汉市第三医院胸外科，湖北武汉 430061)])]), Author(id=1292126439395058060, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1292126436094140797, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=myr7n7@163.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1292126439562830222, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1292126436094140797, authorId=1292126439395058060, language=EN, stringName=Chen-ming ZHANG, firstName=Chen-ming, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=², address=^2.Department of Orthopedics, Wuhan Third Hospital, Wuhan 430061, Hubei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1292126439625744783, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1292126436094140797, authorId=1292126439395058060, language=CN, stringName=张臣鸣, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=², address=^2.武汉市第三医院骨科，湖北武汉 430061, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1292126438887547267, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1292126436094140797, xref=2., ext=[AuthorCompanyExt(id=1292126438895935876, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1292126436094140797, companyId=1292126438887547267, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=^2.Department of Orthopedics, Wuhan Third Hospital, Wuhan 430061, Hubei Province, China), AuthorCompanyExt(id=1292126438904324485, tenantId=1146029695717560320, journalId=1246415772164075586, articleId=1292126436094140797, companyId=1292126438887547267, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=^2.武汉市第三医院骨科，湖北武汉 430061)])])]

潘越¹, 张臣鸣²

作者信息

^1.武汉市第三医院胸外科，湖北武汉 430061

^2.武汉市第三医院骨科，湖北武汉 430061

通讯作者:

张臣鸣，主治医师 Tel: （027）68894680 E-mail: myr7n7@163.com

作者简介:

潘越（1992-），女，主治医师，主要从事乳腺癌及肺癌方面的临床工作和研究

Research on the synergistic inhibition of malignant behavior of breast cancer cells by curcumin and chidamide based on IFN-RIG-I-MAVS pathway

Yue PAN¹, Chen-ming ZHANG²

Affiliations

^1.Department of Thoracic Surgery, Wuhan Third Hospital, Wuhan 430061, Hubei Province, China

^2.Department of Orthopedics, Wuhan Third Hospital, Wuhan 430061, Hubei Province, China

出版时间: 2026-01-17 doi: 10.13699/j.cnki.1001-6821.2026.01.010

文章导航

摘要

收起

目的

探索姜黄素（CUR）与西达苯胺（CHI）通过干扰素（IFN）-视黄酸诱导基因Ⅰ（RIG-Ⅰ）-线粒体抗病毒信号蛋白（MAVS）通路协同抑制乳腺癌（BC）细胞恶性行为的分子机制。

方法

用乳腺癌细胞MCF-7建立细胞模型。将细胞分为5组，包括空白组（正常培养）、CUR组（20 μmol·L^-1 CUR）、CHI组（10 μmol·L^-1 CHI），联合组（20 μmol·L^-1 CUR+10 μmol·L^-1 CHI）和抑制剂组（sh-IFN+20 μmol·L^-1 CUR+10 μmol·L^-1 CHI）。用3-（4，5-二甲基噻唑-2）-2，5-二苯基四氮唑溴盐（MTT）法检测细胞活力，用平板克隆形成实验法检测细胞增殖能力，用Transwell和细胞划痕实验法检测细胞迁移能力，用蛋白质印迹法（WB）检测凋亡相关蛋白和IFN-RIG-Ⅰ-MAVS通路相关蛋白的相对表达水平。

结果

在0、10、20和40 μmol·L^-1 CUR中，CHI的半数抑制浓度（IC₅₀）分别为（31.48±2.01）、（17.57 ±0.65）、（7.56 ±0.32）和（0.21 ±0.02）μmol·L^-1，10、20和40 μmol·L^-1 CUR与0 μmol·L^-1CUR相比，IC₅₀在统计学上差异均有统计学意义，并呈剂量依赖性（均P<0.05）。空白组、CUR组、CHI组、联合组和抑制剂组的克隆形成数分别为（201.28±23.96）、（113.43±15.59）、（109.93±11.64）、（59.57±6.91）和（87.43±5.04）个；穿膜细胞数分别为（115.03±13.05）、（86.51±9.13）、（77.82±6.68）、（39.54±5.43）和（68.92±3.95）个；划痕修复率分别为（51.29±5.17）%、（32.80±2.94）%、（31.23±3.10）%、（16.07±2.11）%和（26.94±1.95）%；细胞凋亡率分别为（2.21±0.16）%、（12.03±0.85）%、（12.89±0.99）%、（31.62±2.98）%和（16.85±1.04）%；Caspase-3相对表达水平分别为0.38±0.03、0.55±0.03、0.52±0.04、1.12±0.07和0.97±0.05；Caspase-9相对表达水平分别为0.33±0.02、0.53±0.02、0.55±0.04、1.05±0.06和0.60±0.05；Bax相对表达水平分别为0.34±0.03、0.52±0.03、0.53±0.03、1.08±0.07和0.69±0.06；IFN-β相对表达水平分别为0.33±0.03、0.46±0.04、0.53±0.04、1.09±0.10和0.45±0.03；RIG-Ⅰ相对表达水平分别为0.32±0.02、0.57±0.05、0.65±0.04、1.02±0.11和0.59±0.05；MAVS相对表达水平分别为0.34±0.02、0.41±0.03、0.49±0.04、1.04±0.12和0.51±0.04，CUR组和CHI组的上述指标与空白组比较，联合组的上述指标与CUR组和CHI组比较，抑制剂组的上述指标与联合组比较，在统计学上差异均有统计学意义（均P<0.05）。

结论

CUR具有增加BC细胞对CHI敏感性的作用，可以协同CHI发挥抗BC作用，其作用机制与CUR激活IFN-RIG-I-MAVS通路有关。

关键词

姜黄素 / 西达苯胺 / 乳腺癌 / 干扰素-视黄酸诱导基因Ⅰ-线粒体抗病毒信号蛋白通路

Abstract

收起

Objective

To explore the molecular mechanism by which curcumin (CUR) and chidamide (CHI) synergistically inhibit the malignant behaviors of breast cancer (BC) cells through the interferon (IFN)-retinoic acid-inducible gene Ⅰ (RIG-Ⅰ)-mitochondrial antiviral-signaling protein (MAVS) pathway.

Methods

A cellular model was established using MCF-7 breast cancer cells. The cells were divided into five groups: blank group(normol cuttured), CUR group(20 μmol·L^-1 CUR), CHI group(10 μmol·L^-1 CHI), combination group(20 μmol·L^-1 CUR+10 μmol·L^-1 CHI) and inhibitor group(sh-IFN+20 μmol·L^-1 CUR+10 μmol·L^-1 CHI). Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell proliferation capacity was evaluated by plate colony formation assay. Cell migration ability was examined using Transwell and wound healing assays. The relative expression levels of apoptosis-related proteins and IFN-RIG-I-MAVS pathway-associated proteins were detected by Western blotting (WB).

Results

Under CUR concentrations of 0, 10, 20 and 40 μmol·L^-1, the half-maximal inhibitory concentrations (IC₅₀) of CHI were (31.48±2.01), (17.57±0.65), (7.56±0.32) and (0.21±0.02) μmol·L^-1, respectively. Statistically significant dose-dependent reductions in IC₅₀ were observed for CHI when combined with 10, 20 and 40 μmol·L^-1 CUR compared to 0 μmol·L^-1 CUR (all P<0.05). The colony formation numbers were (201.28±23.96) cells for the control group, (113.43±15.59) cells for the CUR group, (109.93±11.64) cells for the CHI group, (59.57±6.91) cells for the combination group, and (87.43±5.04) cells for the inhibitor group, respectively; the numbers of invasive cells were (115.03±13.05), (86.51±9.13), (77.82±6.68), (39.54±5.43) and (68.92±3.95) cells, respectively; the wound closure rates were (51.29±5.17)%, (32.80±2.94)%, (31.23±3.10)%, (16.07±2.11)% and (26.94±1.95)%, respectively; the apoptosis rates were (2.21±0.16)%, (12.03±0.85)%, (12.89±0.99)%, (31.62±2.98)% and (16.85±1.04)%, respectively; the relative expression levels of Caspase-3 were 0.38±0.03, 0.55±0.03, 0.52±0.04, 1.12±0.07 and 0.97±0.05, respectively; the relative expression levels of Caspase-9 levels were 0.33±0.02, 0.53±0.02, 0.55±0.04, 1.05±0.06 and 0.60±0.05, respectively; the relative expression levels of Bax levels were 0.34±0.03, 0.52±0.03, 0.53±0.03, 1.08±0.07 and 0.69±0.06, respectively; the relative expression levels of IFN-β levels were 0.33±0.03, 0.46±0.04, 0.53±0.04, 1.09±0.10 and 0.45±0.03, respectively; the relative expression levels of RIG-Ⅰ levels were 0.32±0.02, 0.57±0.05, 0.65±0.04, 1.02±0.11 and 0.59±0.05, respectively; and the relative expression levels of MAVS levels were 0.34±0.02, 0.41±0.03, 0.49±0.04, 1.04±0.12 and 0.51±0.04, respectively. Statistically significant differences were observed when comparing the CUR and CHI groups to the control group, the combination group to the CUR and CHI groups, and the inhibitor group to the combination group (all P<0.05).

Conclusion

CUR enhances the sensitivity of BC cells to CHI and synergistically exerts anti-BC effects with CHI, and its mechanism of action is related to the activation of the IFN-RIG-I-MAVS pathway by CUR.

Key words

curcumin / chidamide / breast cancer / interferon-retinoic acid-inducible gene Ⅰ-mitochondrial antiviral-signaling protein pathway

引用本文

潘越, 张臣鸣. 姜黄素与西达苯胺基于IFN-RIG-I-MAVS通路协同抑制乳腺癌细胞恶性行为的研究. 中国临床药理学杂志, 2026 , 42 (1) : 59 -65 . DOI: 10.13699/j.cnki.1001-6821.2026.01.010

Yue PAN, Chen-ming ZHANG. Research on the synergistic inhibition of malignant behavior of breast cancer cells by curcumin and chidamide based on IFN-RIG-I-MAVS pathway[J]. Chinese Journal of Clinical Pharmacology, 2026 , 42 (1) : 59 -65 . DOI: 10.13699/j.cnki.1001-6821.2026.01.010

基金

收起

武汉市中医药科研基金资助项目(WZ24Q18)
武汉市医学科学研究基金资助项目(WX23Z29)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

2026年第42卷第1期

PDF下载

136

引用本文

BibTeX

文章信息

doi: 10.13699/j.cnki.1001-6821.2026.01.010

接收时间：2025-11-27
首发时间：2026-08-06
出版时间：2026-01-17

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-11-27

基金

武汉市中医药科研基金资助项目(WZ24Q18)

武汉市医学科学研究基金资助项目(WX23Z29)

作者信息

^1.武汉市第三医院胸外科，湖北武汉 430061

^2.武汉市第三医院骨科，湖北武汉 430061

通讯作者:

张臣鸣，主治医师 Tel: （027）68894680 E-mail: myr7n7@163.com

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zglcylxzz/CN/10.13699/j.cnki.1001-6821.2026.01.010

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT